A clinical-stage biotechnology company in Immuno-Oncology and Immuno-Inflammation

Focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

Our latest press release

Read more


Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371


To receive OSE Immunotherapeutics’ latest news